Linda JD - Northwest Biotherapeutics CEO, Chairperson

NWBO Stock

USD 0.29 0.01 3.33%

Insider

Linda JD is CEO, Chairperson of Northwest Biotherapeutics

Age	67
Phone	240 497-9024
Web	www.nwbio.com

Northwest Biotherapeutics Management Efficiency

The company has return on total asset (ROA) of (1.2576) % which means that it has lost $1.2576 on every $100 spent on assets. This is way below average. Northwest Biotherapeutics' management efficiency ratios could be used to measure how well Northwest Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Northwest Biotherapeutics to Peers

Predict price of Northwest Biotherapeutics

Northwest Biotherapeutics currently holds 25.16 M in liabilities. Northwest Biotherapeutics has a current ratio of 0.1, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Northwest Biotherapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Northwest Biotherapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Northwest Biotherapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Northwest to invest in growth at high rates of return. When we think about Northwest Biotherapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Joel Rothman	Equillium	55
	Scott CA	DiaMedica Therapeutics	59
	Laetitia BachelotFontaine	Valneva SE ADR	N/A
	Maurice Zauderer	Vaccinex	78
	Brigid Makes	Vivani Medical	68
	Perry Celentano	Valneva SE ADR	N/A
	Lisa MD	Vivani Medical	60
	Annie McGuire	Veracyte	44
	Tracy Morris	Veracyte	N/A
	Joseph Mara	Vericel Corp Ord	48
	Jonathan Siegal	Vericel Corp Ord	N/A
	Gerald Strohmaier	Valneva SE ADR	N/A
	Adam Mendelsohn	Vivani Medical	42
	Alexander MD	Denali Therapeutics	51
	Beverly CPA	Veracyte	61
	Truc MBA	Vivani Medical	71
	Kayte Fischer	Vivani Medical	N/A
	Jonathan Wygant	Veracyte	53
	MBA CFA	Vaccinex	50
	Edward Calamai	DiaMedica Therapeutics	N/A
	Joe Lewcock	Denali Therapeutics	N/A

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Northwest Bioth operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 19 people. Northwest Biotherapeutics [NWBO] is traded as part of a regulated electronic over-the-counter service offered by the NASD. Northwest Biotherapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Management Performance

Return On Asset

-1.26

Northwest Biotherapeutics Leadership Team

Elected by the shareholders, the Northwest Biotherapeutics' board of directors comprises two types of representatives: Northwest Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Northwest. The board's role is to monitor Northwest Biotherapeutics' management team and ensure that shareholders' interests are well served. Northwest Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Northwest Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Leslie Goldman, Sr. VP of Bus. Devel.
	Linda JD, CEO, Chairperson
	Alton Boynton, Founder, Chief Scientific Officer, Secretary and Director
	David Innes, VP Relations
	Jean Davis, Chief Officer

Northwest Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Northwest Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-1.26
	Profit Margin	52.10 %
	Operating Margin	(54.95) %
	Current Valuation	1.03 B
	Shares Outstanding	1.05 B
	Shares Owned By Insiders	10.04 %
	Shares Owned By Institutions	0.23 %
	Number Of Shares Shorted	14.14 M
	Price To Earning	58.17 X
	Price To Sales	858.96 X

Pair Trading with Northwest Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Northwest Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Northwest Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Northwest OTC Stock

0.77	DRUG	Bright Minds Biosciences	Pair Corr
0.61	SABSW	SAB Biotherapeutics	Pair Corr
0.56	VANI	Vivani Medical	Pair Corr
0.41	VCYT	Veracyte	Pair Corr
0.38	VCEL	Vericel Corp Ord	Pair Corr

The ability to find closely correlated positions to Northwest Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Northwest Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Northwest Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Northwest Biotherapeutics to buy it.

The correlation of Northwest Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Northwest Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Northwest Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Northwest Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Northwest OTC Stock

Northwest Biotherapeutics financial ratios help investors to determine whether Northwest OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Northwest with respect to the benefits of owning Northwest Biotherapeutics security.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC